Drugs

A new report describes three cases of accidental LSD overdoses leading to strangely positive outcomes, including the story of a woman who inadvertently took 500 times a normal dose. New Atlas spoke to Mark Haden, one of the report's authors, to learn more.

A meta-study has reviewed over 50 trials from the last 20 years testing herbal medicines for weight loss, revealing herbal supplements are largely ineffective in aiding weight loss, and one researcher on the project says they are a “waste of money.”

The best way to fight off cancer might be to strengthen the body’s immune system to help identify and kill tumors. This is known as immunotherapy. Now researchers have developed artificial nanoparticles that should be cheaper and easier to produce.

Scientists have pieced together 10 devices that mimic the functions of different organs to create a functioning Body-on-Chips platform, which can offer new and comprehensive insights into how prospective drugs will behave throughout the human body.

Researchers at Instituto Gulbenkian de Ciência (IGC) in Portugal and Stanford in the US have identified one particular bacterium, Klebsiella michiganensis, that could be administered after a round of antibiotics to help prevent harmful infections.

Scientists at Purdue University have come up with en edible security tag that can be integrated into medicine and emit distinctive light patterns when exposed to LED lights as a way to guarantee its safety and authenticity.

A new study has described the discovery of a previously unknown cannabinoid. Dubbed THCP, the molecule is significantly more potent that its well-known counterpart THC, however, it is unknown how present it is in common cannabis strains.

New Atlas spoke to several leading psychedelic researchers to get their thoughts on three big future-forward questions. Where will psychedelic science be in 2030, what hurdles do researchers face, and what research topic is yet to be answered?

Continuing the wave of cutting-edge new migraine drugs reaching the American market, the U.S. Food and Drug Administration (FDA) has now approved the first oral calcitonin gene-related peptide (CGRP) antagonist for acute migraine treatment.

Results have been published from one of the first placebo-controlled clinical trials investigating the effects of microdosing LSD. This Phase 1 trial is exploring whether microdosing could be useful as a therapeutic tool to treat Alzheimer’s disease.

Researchers are reporting positive results from an early trial exploring the safety profile of psilocybin doses in healthy adults. The trial also explored the potential of group dosing sessions as a way to speed up research and expand patient access.

Predicting a wave of psychedelic legalization over the coming decade, start-up Silo Wellness has developed a magic mushroom nasal spray focused on delivering controlled psychedelic microdoses. New Atlas spoke to CEO Mike Arnold to learn more.